Hurles Group
Genomic mutation and genetic disease
We use experimental model systems, especially cells, to understand the biology of these conditions in greater detail. We also study how DNA mutates as it is passed from one generation to the next, and the factors that influence the number and type of mutations that arise. We are a multi-disciplinary group of molecular biologists, bioinformaticians and computational geneticists.
Core team
Malin Andersson
Technical Specialist
Dr Petr Danecek
Statistical Genetics Analyst
Dr Sebastian Gerety
Senior Staff Scientist
Dr Rachel J Hobson
Data Coordinator
Dr Sarah J Lindsay
Senior Staff Scientist
Previous core team members
Dr Nadia Akawi
Postdoctoral Fellow
Mohamed Almarri
PhD Student
Rizwan Ansari
Advanced Research Assistant
Kartik Chundru
Postdoctoral Fellow
Christina Dias
Visiting Scientist
Dr Giuseppe Gallone
Former Senior Computer Biologist at the Sanger Institute
Dr Eugene Gardner
Postdoctoral Fellow
Sophie Hackinger
PhD Student
Dr Konstantinos Hatzikotoulas
Postdoctoral Fellow
Liu He
Postdoctoral Fellow
Ximena Ibarra-Soria
PhD Student
Phil Jones
DDD Informatics Team Manager
Joanna Kaplanis
Post doctoral fellow
Dr Ro (Rosemary) Kelsell
Project Administrator
Darren Logan
Former CDF Group Leader
Dr Jenny Lord
Postdoctoral Fellow
Jeremy McRae
Statistical Geneticist
Dr Emmanouil Metzakopian
Career Development Fellow
Dr Joshua C. Randall
Senior Scientific Manager
Dr Gabriele Rinck
Project Manager
Patrick Short
PhD Student, Wellcome Trust PhD in Mathematical Genomics and Medicine
Dr Jawahar Swaminathan
Senior Scientific Manager (DECIPHER Project Manager)
Elizabeth Wynn
Advanced Research Assistant
Eleftheria Zeggini
Former Group Leader
Associated research
Related groups
Programmes and Facilities
Partners
We work with the following groups
External
Health Innovation Challenge Fund
The DDD and PAGE studies are funded by the Health Innovation Challenge Fund, a parallel funding partnership between the Wellcome Trust and the Department of Health to stimulate the creation of innovative healthcare products, technologies and interventions and to facilitate their development for the benefit of patients in the NHS and beyond.